Thyroid Cancer

Exelixis announced that its cabozantinib tablet received FDA approval for patients aged 12 years and older who have previously treated radioactive iodine-refractory differentiated thyroid cancer.

The FDA and Federal Trade Commission recently warned against dietary supplements that unlawfully claim to cure, treat or prevent diabetes. It was the top story in endocrinology last week.

Molecular testing was the best predictor for malignancy in indeterminate thyroid nodules when compared with clinical factors, according to findings from a post hoc analysis published in Thyroid.

Adults with differentiated thyroid cancer who undergo thyroidectomy are at increased risks for atrial fibrillation, cardiovascular disease, increased heart rate and left ventricular mass development, data from a review show.

Women are about four times more likely than men to be diagnosed with papillary thyroid cancer during their lifetime, even though the prevalence of thyroid cancer at autopsy is roughly the same in men and women, according to study findings.

Recent data revealed the Right to Try track did not more successfully help oncologists obtain investigational drugs than Expanded Access, which has an extra step of receiving FDA authorization for each patient.

Accurate risk stratification during the immediate perioperative period that incorporates molecular theranostics can help better guide decision-making for thyroid cancer treatment, according to a new joint statement published in Thyroid.

Thyroid cancer incidence is increasing at a rate faster than that of any other cancer.

Thyroid nodules are common. Each year, approximately 600,000 U.S. residents with nodules undergo a fine-needle aspiration biopsy in which cells are extracted and examined to determine whether the nodule is benign or cancerous.

Radioactive iodine therapy targets the thyroid gland, but it also inadvertently exposes other organs and tissues to low to moderate doses of radiation.